Case study: MSIntuit® CRC
Authors
Case study: MSIntuit® CRC
Authors
About Owkin
Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.
We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.
Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).
A pre-screen approach for MSI from digitized H&E slides
Context
Microsatellite instability (MSI) is a genomic biomarker that plays an important role in the treatment of colorectal tumours (CRC) patients. MSI is predictive of response to immunotherapy across all solid tumors.
Methods
We developed MSIntuit, an AI based pre-screening tool for MSI detection of CRC from H&E WSI, and performed the first successful blind validation confirming its robustness for clinical applications.
Results
MSIntuit CRC reaches sensitivity comparable to gold standard methods (92-95%) while ruling out almost half of the MSS patients.
MSIntuit CRC is an interpretable model - it highlights the parts of the slide image used to make its predictions.
Impact
With a sensitivity of ~95%, MSIntuit CRC can help rule out 40% of CRC patients from reflex screening with standard MMR/MSI testing techniques.
Learn more about MSIntuit CRC